Improving outcome in acute coronary syndromes - As good as it gets?

European Heart Journal

Volumn 20, Issue 21, 1999, Pages 1533-1537

  Purcell, H ^a   Fox, K M ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEFRADAFIBAN; NITRATE; ORBOFIBAN; PRAVASTATIN; ROXITHROMYCIN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; WARFARIN; XEMILOFIBAN;

BLEEDING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; SIDE EFFECT; STOMACH DISEASE; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; SYNDROME; TREATMENT OUTCOME;

EID: 0032717204     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1765     Document Type: Review

References (37)

1. Graves, EJ, National hospital discharge survey: annual summary, 1991, 1993.
2. N Engl J Med. 335:1996;775-782.
3. Lewis HD Jr, Davis JW, Archibald DG. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 309:1983;396-403.
4. Rizik D, Timmis GC, Grines CL, Bakalyar D, Schreiber T. Immediate use of beta blockers, but not calcium blockers, improves prognosis in unstable angina (Abstr). Circulation. 84:1991;II345.
5. Eur Heart J. 56:1986;400-413.
6. ATPchannel in unstable angina. Eur Heart J. 20:1999;51-57.
7. Patel DJ, Knight CJ, Holdright DR. Long-term prognosis in unstable angina. The importance of early risk stratification using continuous ST segment monitoring. Eur Heart J. 19:1998;240-249.
8. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. Circulation. 96:1997;2578-2585.
9. Lindahl B, Andren B, Ohisson J, Venge P, Wallentin L. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. Eur Heart J. 18:1997;762-770.
10. Boden WE, O'Rourke RA, Crawford MH. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 338:1998;1785-1792.
11. Yusuf S, Flather M, Pogue J. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet. 352:1998;507-514.
12. Halon DA, Flugelman MY, Merdler A, Rennert H, Shahla J, Lewis BS. Long-term (10 year) outcome in patients with unstable angina pectoris treated by coronary balloon angioplasty. J Am Coll Cardiol. 32:1998;1603-1609.
13. Cannon CP, Weintraub WS, Demopoulos, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 trial. Am J Cardiol. 82:1998;731-736.
14. Lancet. 354:1999;708-715.
15. Circulation. 89:1994;1545-1556.
16. Br J Cardiol. 6:1999;192-196.
17. Ridker PM, Rifai N, Pfeffer MA. Inflammation, pravastatin, and risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
18. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS a pilot study. Lancet. 350:1997;404-407.
19. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J. 20:1999;121-127.
20. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulation therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation. 98:1998;1064-1070.
21. Purcell H, Fox KM. Current roles and future possibilities for low-molecular-weight heparins in unstable angina. Eur Heart J. 19:1998;K18-K23.
22. Lancet. 347:1996;561-568.
23. Klein W, Buchwald A, Hillis SE. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 96:1997;61-68.
24. Lancet. 354:1999;701-707.
25. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452.
26. Cohen M, Bigonzi F, Le Louer V, Gosset F, Fromell GJ, Goodman S. One year follow-up of the ESSENCE Trial (enoxaparin versus heparin in unstable angina and Non-Q-Wave myocardial infarction). J Am Coll Cardiol. 31:1998;79A.
27. Verheught FWA. Hotline sessions at the 20th European Congress of Cardiology. Eur Heart J. 20:1998;7-10.
28. Eur Heart J. 20:1999;1553-1562.
29. Montalescot G, Philippe F, Ankri A. Early increase in von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation. 98:1998;294-299.
30. Lancet. 353:1999;429-438.
31. Braunwald E, Maseri A, Armstrong PW. Rationale and clinical evidence for use of GP IIb/IIIa inhibitors in acute coronary syndromes. Am Heart J. 135:1998;S56-S66.
32. Lancet. 349:1997;1429-1435.
33. Ronner E, Dykun Y, van den Brand MJBM, van der Wieken LR, Simoons ML. Platelet glycoprotein IIb/IIIa receptor antagonists. Eur Heart J. 19:1998;1608-1616.
34. Wilcox, R, Presentation, 1999.
35. Hughes S. Speculation rife on orbofiban mortality. Scrip. 22:1998.
36. Goy J-J. Contemporary approach to management of unstable angina. Lancet. 354:1999;694-695.
37. Clinical practice guideline-unstable angina: diagnosis and management.